vs
Apellis Pharmaceuticals, Inc.（APLS）与艺达思集团（IEX）财务数据对比。点击上方公司名可切换其他公司
艺达思集团的季度营收约是Apellis Pharmaceuticals, Inc.的2.0倍（$398.4M vs $199.9M），艺达思集团净利率更高（30.1% vs -29.5%，领先59.6%），艺达思集团同比增速更快（16.7% vs -5.9%），艺达思集团自由现金流更多（$86.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -29.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
艺达思集团是一家公开上市的工业制造企业，专注于流体系统与特种工程产品的研发和生产，产品广泛应用于工业制造、生命科学、食品安全等多个领域，可为全球各行业客户提供高性能定制化解决方案。
APLS vs IEX — 直观对比
营收规模更大
IEX
是对方的2.0倍
$199.9M
营收增速更快
IEX
高出22.6%
-5.9%
净利率更高
IEX
高出59.6%
-29.5%
自由现金流更多
IEX
多$100.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
-29.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $398.4M |
| 净利润 | $-59.0M | $120.0M |
| 毛利率 | — | 99.9% |
| 营业利润率 | -25.6% | 43.3% |
| 净利率 | -29.5% | 30.1% |
| 营收同比 | -5.9% | 16.7% |
| 净利润同比 | -62.2% | 25.7% |
| 每股收益（稀释后） | $-0.40 | $1.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSIEX
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $199.9M | $899.1M | ||
| Q3 25 | $458.6M | $878.7M | ||
| Q2 25 | $178.5M | $865.4M | ||
| Q1 25 | $166.8M | $814.3M | ||
| Q4 24 | $212.5M | $862.9M | ||
| Q3 24 | $196.8M | $798.2M |
净利润APLSIEX
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $-59.0M | $128.3M | ||
| Q3 25 | $215.7M | $127.8M | ||
| Q2 25 | $-42.2M | $131.6M | ||
| Q1 25 | $-92.2M | $95.5M | ||
| Q4 24 | $-36.4M | $123.2M | ||
| Q3 24 | $-57.4M | $119.1M |
毛利率APLSIEX
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | — | 43.1% | ||
| Q3 25 | — | 44.5% | ||
| Q2 25 | — | 45.3% | ||
| Q1 25 | — | 45.3% | ||
| Q4 24 | — | 42.5% | ||
| Q3 24 | — | 44.3% |
营业利润率APLSIEX
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | -25.6% | 20.4% | ||
| Q3 25 | 48.7% | 21.1% | ||
| Q2 25 | -18.6% | 21.7% | ||
| Q1 25 | -50.0% | 17.4% | ||
| Q4 24 | -12.3% | 19.2% | ||
| Q3 24 | -24.0% | 21.0% |
净利率APLSIEX
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | -29.5% | 14.3% | ||
| Q3 25 | 47.0% | 14.5% | ||
| Q2 25 | -23.6% | 15.2% | ||
| Q1 25 | -55.3% | 11.7% | ||
| Q4 24 | -17.1% | 14.3% | ||
| Q3 24 | -29.2% | 14.9% |
每股收益（稀释后）APLSIEX
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $-0.40 | $1.71 | ||
| Q3 25 | $1.67 | $1.70 | ||
| Q2 25 | $-0.33 | $1.74 | ||
| Q1 25 | $-0.74 | $1.26 | ||
| Q4 24 | $-0.30 | $1.61 | ||
| Q3 24 | $-0.46 | $1.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $586.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $4.0B |
| 总资产 | $1.1B | $6.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSIEX
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $466.2M | $580.0M | ||
| Q3 25 | $479.2M | $593.8M | ||
| Q2 25 | $370.0M | $568.2M | ||
| Q1 25 | $358.4M | $594.1M | ||
| Q4 24 | $411.3M | $620.8M | ||
| Q3 24 | $396.9M | $633.2M |
总债务APLSIEX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.1B |
股东权益APLSIEX
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $370.1M | $4.0B | ||
| Q3 25 | $401.2M | $4.0B | ||
| Q2 25 | $156.3M | $4.0B | ||
| Q1 25 | $164.2M | $3.9B | ||
| Q4 24 | $228.5M | $3.8B | ||
| Q3 24 | $237.1M | $3.8B |
总资产APLSIEX
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $1.1B | $6.9B | ||
| Q3 25 | $1.1B | $7.0B | ||
| Q2 25 | $821.4M | $6.9B | ||
| Q1 25 | $807.3M | $6.8B | ||
| Q4 24 | $885.1M | $6.7B | ||
| Q3 24 | $901.9M | $7.0B |
负债/权益比APLSIEX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $86.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 21.6% |
| 资本支出强度资本支出/营收 | 0.1% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $654.3M |
8季度趋势，按日历期对齐
经营现金流APLSIEX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $209.5M | ||
| Q3 25 | $108.5M | $203.5M | ||
| Q2 25 | $4.4M | $161.7M | ||
| Q1 25 | $-53.4M | $105.7M | ||
| Q4 24 | $19.4M | $172.6M | ||
| Q3 24 | $34.1M | $205.3M |
自由现金流APLSIEX
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | $-14.3M | $189.8M | ||
| Q3 25 | $108.3M | $188.7M | ||
| Q2 25 | $4.4M | $146.9M | ||
| Q1 25 | $-53.4M | $91.4M | ||
| Q4 24 | $19.3M | $157.1M | ||
| Q3 24 | — | $191.6M |
自由现金流率APLSIEX
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | -7.1% | 21.1% | ||
| Q3 25 | 23.6% | 21.5% | ||
| Q2 25 | 2.5% | 17.0% | ||
| Q1 25 | -32.0% | 11.2% | ||
| Q4 24 | 9.1% | 18.2% | ||
| Q3 24 | — | 24.0% |
资本支出强度APLSIEX
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | 0.1% | 2.2% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.0% | 1.8% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 1.7% |
现金转化率APLSIEX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 1.63× | ||
| Q3 25 | 0.50× | 1.59× | ||
| Q2 25 | — | 1.23× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
IEX
暂无分部数据
